Research programme: zirconium-89-conjugated imaging agents - Telix Pharmaceuticals

Drug Profile

Research programme: zirconium-89-conjugated imaging agents - Telix Pharmaceuticals

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Telix Pharmaceuticals
  • Developer Peter MacCallum Cancer Centre; Telix Pharmaceuticals; University of Melbourne
  • Class Imaging agents; Protein diagnostics; Radioisotopes
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 18 Oct 2017 Telix Pharmaceuticals and the University of Melbourne agree to co-develop zirconium-89-conjugated imaging agents in Australia for Prostate cancer, Renal cancer and Colorectal cancer
  • 18 Oct 2017 Telix Pharmaceuticals in-licenses zirconium-89 protein conjugation technology from the University of Melbourne
  • 18 Oct 2017 Early research in Cancer (Diagnosis) in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top